张健慧;邵一鸣;

• 1:中国疾病预防控制中心性病艾滋病预防控制中心
• 2:中国疾病预防控制中心性病艾滋病预防控制中心 北京100050
• 3:北京100050

摘要(Abstract)：

全球艾滋病流行的严峻趋势迫切需要研制安全、有效、价廉的艾滋病疫苗。尽管国际上艾滋病疫苗研究已有20年的历史,但仍然未获成功。该文将就国际艾滋病疫苗的研究历史、发展阶段、研发特点进行综述,并重点回顾国内外艾滋病疫苗临床试验的进展情况,并对艾滋病疫苗的研发策略进行探讨。

关键词(KeyWords)： 艾滋病疫苗;临床试验;研发策略

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 张健慧;邵一鸣;

参考文献(References)：

• [1]IAVI database of AIDS vaccines in human trials[EB/OL].http://www.iavireport.org/trialsdb
• [2]Mascola JR,Snyder SW,Weislow OS,et al.I mmunization with en-velope subunit vaccine products elicits neutralizing antibodies againstlaboratoryadapted but not pri maryisolates of humani mmunodeficiencyvirus type 1.The National Institute of Allergy andInfectious DiseasesAIDS Vaccine Evaluation Group[J].J Infect Dis,1996,173:340-348.
• [3]Mitka M.Critics bash HI Vvaccine trial analysi s[J].Jama,2003,289:1491.
• [4]Check E.Army HI Vvaccine to undergo clinical trial as rival is halted[J].Nature,2002,416:6.
• [5]Burton DR,Desrosiers RC,Doms RW,et al.Public health.ASound Rationale Needed for PhaseⅢHI V-1 Vaccine Trial[J]s.Sci-ence,2004,303:316.
• [6]Frantz S.Scientists slamrationale behind largest HI V vaccine trial.[J]Nat Rev Drug Discov,2004,3:195.
• [7]Mwau M,Cebere I,Sutton J,et al.A human i mmunodeficiencyvirus 1(HI V-1)clade Avaccinein clinical trials:sti mulation of HI V-specific T-cell responses by DNA and recombinant modified vacciniavirus Ankara(MVA)vaccinesin humans[J].J Gen Virol,2004,85:911-919.
• [8]Jaoko W.Safety andi mmunogenicty of DNAand MVA HI VA Vac-cines in phase I HI V-1 vaccine trials in Nairobi,Kenya[C].AIDSVaccine 04 Conference Lausanne Switzerland.WWW.AIDSVaccine04.org.
• [9]Emini,E.A.Ongoing development and evaluation of a potentialHI V-1 vaccine using a replication-defective adenoviral vector[C].Presented at the Keystone Symposium on HI V-1 Vaccine Develop-ment,2003,Banff,Canada.
• [10]Morral N,O’Neal WK,Rice K,et al.Beaudet,and C.Langston.Lethal toxicity,severe endothelial injury,and a threshold effectwith high doses of an adenoviral vector in baboons[J].Hum.GeneTher,2002,13:143-154.
• [11]Gahery-Segard H,Pialoux G,Figueiredo S,et al.Selection of virusvariants and emergence of virus escape mutants after i mmunizationwith an epitope vaccine[J].J Virol,1998,72:1403-1410.
• [12]Warren J.Preclinical AIDS vaccine research:survey of SI V,SHI V,and HI Vchallenge studiesin vaccinated nonhuman pri mates[J].J Med pri matol,2002,31:237-256.
• [13]Corey L,McElrath MJ,Weinhold K,et al.Cytotoxic T cell andneutralizing antibody responses to human i mmunodeficiency virustype 1 envelope with a combination vaccine regi men.AIDS VaccineEvaluation Group[J].J Infect Dis,1998,177:301-309.
• [14]Ackers ML,Parekh B,Evans TG,et al.Humani mmunodeficiencyvirus(HI V)seropositivity among uninfected HI Vvaccine recipients[J].J Infect Dis,2003,187:879-886.
• [15]Slobod,K.S.Clinical Evaluation of the First Multi-Envelope HI V-1 Vaccine:a 23 Envelope Recombinant Vaccinia Virus Cocktail(Abstract No.52)[C].AIDS Vaccine 2003 Meeting.2003,NewYork,US.
• [16]全国各地防疫站及生物制品研究所.1974年痘苗经验交流会资料汇编[C].1974,69-164.
• [17]Peng B,Wang LR,Gomez-Roman VR,et al.Replicating ratherthan nonreplicating adenovirus-human i mmunodeficiency virus re-combinant vaccines are better at eliciting potent cellular i mmunityand pri ming high-titer antibodies[J].J Virol,2005,79:10200-10209.
• [18]Malkevitch NV,Robert-Guroff M.A call for replicating vectorpri me-protein boost strategies in HI V vaccine design[J].ExpertRev Vaccines,2004,3:S105-117.